关于江苏吉贝尔药业股份有限公司 非经营性资金占用及其他关联资金往来情况 汇总表的专项审计报告 目 录 1、 专项审计报告 2、 附表 委托单位：江苏吉贝尔药业股份有限公司 审计单位：信永中和会计师事务所（特殊普通合伙） 联系电话：联系电话：+86（010）6554 2288 江苏吉贝尔药业股份有限公司 2024 年度 非经营性资金占用及其他关联资金往来的 专项说明 | 索引 | 页码 | | --- | --- | | 专项说明 | 1-2 | | 非经营性资金占用及其他关联资金往来情况汇总表 | - | 江苏吉贝尔药业股份有限公司全体股东: 我们按照中国注册会计师审计准则审计了江苏吉贝尔药业股份有限公司(以下简称 吉贝尔公司)2024年度财务报表,包括2024年12月31日的合并及母公司资产负债表、 2024 年度的合并及母公司利润表、合并及母公司现金流量表、合并及母公司股东权益变 动表以及财务报表附注,并于 2025年4月14日出具了 XYZH/2025SHAA2B0041 号无保留 意见的审计报告。 根据中国证券监督管理委员会《上市公司监管指引第8号 -- 上市公司资金往来、 对外担保的监管要求》(证监 ...

江苏吉贝尔药业股份有限公司 董事会审计委员会 2024 年度履职情况报告 1 金投向属于科技创新领域的说明（修订稿）的议案》《关于公司非经常性损益明 细表的议案》《公司 2023 年 1-9 月内部控制评价报告》《关于开设以简易程序向 特定对象发行股票募集资金专项账户并授权签署募集资金监管协议的议案》。 3、2024 年 4 月 17 日，公司第四届董事会审计委员会第四次会议，审议通 过了《公司 2023 年年报审计完成阶段治理层沟通报告》。 一、审计委员会基本情况 公司董事会下设审计委员会，作为对公司财务收支和经济活动进行内部审计 监督的专门工作机构。因公司前独立董事杨国祥先生、谢竹云先生、何娣女士自 2018 年 5 月起在公司连续担任独立董事至今满六年，三位独立董事申请辞去公 司第四届董事会独立董事职务，同时辞去董事会下设各专门委员会委员职务。选 举相关新任独立董事前，公司董事会审计委员会由谢竹云、杨国祥、何娣三名独 立董事组成，其中谢竹云先生为会计专业人士，担任主任委员，为会议召集人。 目前，公司董事会审计委员会由陈留平、范明、刘同君三名独立董事组成， 其中陈留平先生为会计专业人士，担任主任委员，为会 ...

经深入核查公司现任独立董事范明先生、陈留平先生、刘同君先生以及 2024 年 5 月离任的独立董事杨国祥先生、谢竹云先生、何娣女士的任职经历及个人签 署的相关自查文件，确认各位独立董事在报告期内未在公司担任除独立董事以外 的任何职务，亦未在公司的主要股东单位中担任任何职务。独立董事与公司及其 主要股东之间不存在任何形式的利益冲突、关联关系或其他可能对其独立客观判 断产生影响的情况。公司独立董事在 2024 年度始终保持高度的独立性，其履职 行为符合《上市公司独立董事管理办法》《上市公司治理准则》以及《公司章程》 中关于独立董事独立性的严格规定和要求，有效地履行了独立董事的职责，为公 司决策提供了公正、独立的专业意见。 江苏吉贝尔药业股份有限公司董事会 2025 年 4 月 14 日 1 江苏吉贝尔药业股份有限公司 董事会关于独立董事独立性自查情况的 专项报告 一、独立董事独立性自查情况 根据《上市公司独立董事管理办法》第六条的规定，江苏吉贝尔药业股份有 限公司（以下简称"公司"）现任独立董事范明先生、陈留平先生、刘同君先生 以及 2024 年 5 月离任的独立董事杨国祥先生、谢竹云先生、何娣女士对其在担 任公 ...

证券代码：688566 证券简称：吉贝尔 江苏吉贝尔药业股份有限公司 2025 年度"提质增效重回报" 行动方案 二〇二五年四月 | 一、拥有多个独家品种的医药高新技术企业 2 | | --- | | （一）产品种类丰富，主要产品为独家品种 2 | | （二）拥有核心科技，专注创新药研发 3 | | （三）创新驱动，稳健经营彰显企业发展韧性 4 | | 二、多措并举，奋力推动高质量发展 5 | | （一）聚焦主业，专注于药物研发与制造 5 | | （二）创新驱动，持续推进新药研究与开发 6 | | （三）强化管理，提质增效助力高质量发展 7 | | （四）规范运作，持续完善公司治理 8 | | （五）传播价值，强化投资者沟通与交流 8 | | （六）注重回报，切实维护投资者权益 9 | | （七）强化约束，管理层与股东利益共担共享 11 | | （八）落实责任，"关键少数"发挥关键表率作用 11 | | 三、相关说明 12 | 江苏吉贝尔药业股份有限公司（以下简称"公司"）为践行"以 投资者为本"的上市公司发展理念，维护公司全体股东利益，基于对 公司长期发展的信心和"回报股东，回馈社会"社会责任理念，公司 董 ...

证券代码：688566 证券简称：吉贝尔 公告编号：2025-015 江苏吉贝尔药业股份有限公司 2024 年度募集资金存放与实际使用情况的 专项报告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据《中华人民共和国证券法》《上市公司监管指引第 2 号——上市公 司募集资金管理和使用的监管要求》《上海证券交易所科创板股票上市规则》 《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》《江 苏吉贝尔药业股份有限公司募集资金使用管理制度》及相关格式指引的规定， 江苏吉贝尔药业股份有限公司（以下简称"公司"）董事会对公司 2024 年 度募集资金存放与实际使用情况专项说明如下： 截至2023年12月31日止，公司募集资金使用情况如下： 程序向特定对象发行股票 744.6889 万股，每股面值 1.00 元，每股发行价格为 26.61 元，募集资金总额为人民币 198,161,716.29 元，扣除各项发行费用人民币 9,687,596.06 元（不含税）,募集资金净额为人民币 188,474,120.23 元。上 ...

证券代码：688566 证券简称：吉贝尔 公告编号：2025-019 江苏吉贝尔药业股份有限公司 关于召开 2024 年年度股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东大会类型和届次 2024 年年度股东大会 召开日期时间：2025 年 5 月 28 日 14 点 30 分 召开地点：江苏省镇江市高新技术产业开发园区公司会议室 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自 2025 年 5 月 28 日 至 2025 年 5 月 28 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 涉及融资融券、转融通业务、约定购回业务相关账户以及沪股通投资者的投 票，应按照《上海证券交易所科创板上市公司自律监管指引第 1 号 — 规范运作》 等有关规定执行。 （七） 涉及公开征集股东投票权 不涉及。 二、 会议审议事项 本次股东大会审议议案及投票股东类型 1 股东大会召开 ...

证券代码：688566 证券简称：吉贝尔 公告编号：2025-012 江苏吉贝尔药业股份有限公司 第四届监事会第十四次会议公告 本公司监事会及全体监事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 根据《公司法》《公司章程》《公司监事会议事规则》等有关规定，公司监事 会就 2024 年度主要工作回顾及 2025 年度主要工作安排编制了《江苏吉贝尔药业 股份有限公司 2024 年度监事会工作报告》。 表决情况：3 票同意、0 票反对和 0 票弃权。 表决结果：通过。 本议案尚需提交公司股东大会审议。 （二）审议通过《公司 2024 年度财务决算报告》 根据《公司法》《公司章程》等有关规定，公司董事会根据 2024 年度公司整 体经营情况编制了《江苏吉贝尔药业股份有限公司 2024 年度财务决算报告》。 表决情况：3 票同意、0 票反对和 0 票弃权。 江苏吉贝尔药业股份有限公司（以下简称"公司"）第四届监事会第十四次 会议于 2025 年 4 月 3 日以书面方式发出通知，于 2025 年 4 月 14 日在公司会议 室召开 ...

证券代码：688566 证券简称：吉贝尔 公告编号：2025-013 江苏吉贝尔药业股份有限公司 2024 年度利润分配预案公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 每股分配比例：每 10 股派发现金红利人民币 2.60 元（含税），不送 红股，不进行资本公积金转增股本。 本次利润分配以实施权益分派股权登记日登记的总股本为基数，具体 日期将在权益分派实施公告中明确。如在本公告披露之日起至实施权益分派 股权登记日期间公司总股本发生变动的，公司拟维持分配总额不变，相应调 整每股分配比例，并将另行公告具体调整情况。 本次利润分配符合相关法律法规及《公司章程》的规定，不触及《上 海证券交易所科创板股票上市规则》第 12.9.1 条第一款第（八）项规定的可 能被实施其他风险警示的情形。 一、利润分配方案内容 （一）利润分配方案的具体内容 经信永中和会计师事务所（特殊普通合伙）审计，江苏吉贝尔药业股份 有限公司（以下简称"公司"）2024 年度实现归属于上市公司股东的净利润 为 219,327,779.08 ...

Revenue and Profitability - Revenue for Q1 2025 was CNY 201.80 million, a 3.90% increase compared to CNY 194.23 million in the same period last year[4] - Net profit attributable to shareholders decreased by 5.68% to CNY 49.53 million from CNY 52.51 million year-on-year[4] - Basic and diluted earnings per share decreased by 10.71% to CNY 0.25 from CNY 0.28 in the same period last year[4] - Total operating revenue for Q1 2025 was CNY 201.80 million, a 3.6% increase from CNY 194.23 million in Q1 2024[17] - Net profit for Q1 2025 was CNY 49.45 million, a decrease of 5.6% compared to CNY 52.43 million in Q1 2024[18] - Basic and diluted earnings per share for Q1 2025 were CNY 0.25, down from CNY 0.28 in Q1 2024[19] Cash Flow and Investments - Operating cash flow decreased significantly by 46.29% to CNY 43.99 million, primarily due to a reduction in bank acceptance bill discounts[4][7] - Cash flow from operating activities generated a net amount of CNY 43.99 million in Q1 2025, significantly lower than CNY 81.90 million in Q1 2024[21] - Cash flow from investing activities resulted in a net outflow of CNY 276.86 million in Q1 2025, compared to a net outflow of CNY 303.49 million in Q1 2024[22] - Cash and cash equivalents decreased to CNY 627,550,120.58 from CNY 847,480,374.78, representing a decline of approximately 26%[13] - Cash and cash equivalents at the end of Q1 2025 totaled CNY 626.93 million, an increase from CNY 482.41 million at the end of Q1 2024[22] Research and Development - Total R&D investment increased by 64.28% to CNY 15.93 million, representing 7.89% of revenue, up from 4.99% in the previous year[5][7] - Research and development expenses decreased to CNY 7.84 million in Q1 2025, down from CNY 9.70 million in Q1 2024[17] Assets and Liabilities - Total assets at the end of the reporting period were CNY 2.55 billion, a 0.87% increase from CNY 2.53 billion at the end of the previous year[5] - The company's current assets totaled CNY 1,310,717,373.59, slightly up from CNY 1,304,434,022.07, indicating a marginal increase of about 0.25%[13] - The company's total liabilities decreased to CNY 246,341,993.37 from CNY 273,675,274.92, a reduction of about 10%[15] - The company's long-term equity investments rose to CNY 83,878,587.70 from CNY 79,791,620.21, reflecting an increase of about 5%[14] - The company's inventory increased to CNY 35,139,081.55 from CNY 30,697,954.49, showing a growth of approximately 14.5%[14] - The company's short-term borrowings increased to CNY 23,754,693.09 from CNY 20,828,108.65, indicating an increase of about 14%[15] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 7,292[9] - The top shareholder, Zhenjiang Zhongtian Investment Consulting Co., Ltd., holds 27.28% of the shares, totaling 54.40 million shares[9] - Shareholder equity attributable to shareholders increased by 2.20% to CNY 2.30 billion from CNY 2.25 billion year-on-year[5] - The total equity attributable to shareholders increased to CNY 2,298,167,640.82 from CNY 2,248,637,420.86, marking an increase of approximately 2.2%[15] Future Outlook - The company reported non-recurring gains of CNY 219,450.08, primarily from government subsidies and financial asset disposals[7] - The company is focusing on new product development and market expansion strategies to enhance future growth prospects[16] - The company's net profit for the first quarter of 2025 will be reported in the upcoming earnings release, with expectations of growth based on previous performance trends[16]

Dividend Distribution - The company plans to distribute a cash dividend of RMB 2.60 per 10 shares, totaling RMB 51,852,024.90 (including tax) based on a total share capital of 199,430,865 shares[7]. - The total cash dividends for the year 2024 are expected to reach RMB 154,802,074.70 (including tax) if the proposed distribution plan is approved[8]. - The board of directors has authorized the formulation of a specific mid-term profit distribution plan for 2024[8]. Financial Performance - The company's operating revenue for 2024 reached ¥896,534,453.46, representing a 4.14% increase compared to ¥860,933,244.79 in 2023[24]. - The net profit attributable to shareholders for 2024 was ¥219,327,779.08, a slight increase of 0.11% from ¥219,087,891.18 in 2023[24]. - The net profit after deducting non-recurring gains and losses was ¥215,090,754.66, up 2.85% from ¥209,137,599.61 in 2023[24]. - The net cash flow from operating activities increased by 34.98% to ¥215,293,605.06 in 2024, compared to ¥159,500,018.77 in 2023[24]. - The company's total assets as of the end of 2024 were ¥2,527,540,551.74, reflecting a 14.39% increase from ¥2,209,668,213.23 at the end of 2023[24]. - The net assets attributable to shareholders increased by 18.05% to ¥2,248,637,420.86 at the end of 2024, compared to ¥1,904,838,829.13 at the end of 2023[24]. - The basic earnings per share for 2024 were ¥1.13, a decrease of 3.42% from ¥1.17 in 2023[25]. - The weighted average return on equity decreased to 10.51% in 2024, down from 12.22% in 2023, a reduction of 1.71 percentage points[25]. Research and Development - The R&D expenditure as a percentage of operating revenue increased to 7.85% in 2024, up from 6.48% in 2023[25]. - The company invested a total of 70.41 million yuan in R&D, representing a 26.25% increase year-on-year[36]. - The company has established a comprehensive drug development system, covering all stages from compound screening to industrialization, supported by a professional R&D team[68][69]. - The company is actively engaged in the research and development of innovative drugs for conditions such as depression and tumors[38]. - The company is developing a new antidepressant drug JJH201501, which has completed Phase II clinical trials and is currently in Phase III trials, showing significant efficacy and good safety profile[60]. - The anticancer drug JJH201601 has completed Phase I clinical trials and is now in Phase IIa trials, demonstrating superior tumor suppression effects compared to imported docetaxel injections[61]. - The company is developing a new diabetes treatment using mulberry leaf extracts, with quality standards established and ongoing research on extraction and stability[65]. Product Development and Innovation - The company is advancing multiple new drug projects, including JJH201601 and JJH201701, with significant progress reported[35]. - The company has developed multiple deuterated compounds, including new drugs for depression (JJH201501), gastric acid (JJH201701), gallbladder inflammation and gallstones (JJH201801), and diabetes (JJH202301)[97]. - The company has established various research centers and innovation platforms, contributing to its ongoing technical advancements and product development[114]. - The company’s product range includes treatments for various conditions, such as hypertension, immune enhancement, and joint diseases, catering to diverse market needs[111]. Market and Competitive Landscape - The global pharmaceutical market is projected to reach $1,711.4 billion by 2025, with a CAGR of 5.70% from 2020 to 2025, and $2,105.9 billion by 2030, with a CAGR of 4.20% from 2025 to 2030[76]. - China's pharmaceutical market is expected to reach ¥228.73 billion by 2025, with a CAGR of 9.60% from 2020 to 2025, and ¥299.11 billion by 2030[77]. - The pharmaceutical industry is characterized by high technical, financial, and talent requirements, with significant barriers to entry due to long development cycles and high investment costs[82][83]. - The company aims to expand its market presence and sales scale through optimized marketing strategies and new product development[74]. Corporate Governance - The company has confirmed that all directors are present at the board meeting[5]. - The company has not disclosed any special arrangements for corporate governance[10]. - The board of directors consists of 7 members, including 3 independent directors, ensuring compliance with corporate governance standards[184]. - The company has established a supervisory board consisting of three supervisors, including one employee representative supervisor, ensuring compliance with relevant laws and regulations[185]. Risk Management - The company has outlined various risks in its operations, which are detailed in the management discussion and analysis section[4]. - There are no non-operating fund occupations by controlling shareholders or related parties reported[11]. - The company is closely monitoring macroeconomic risks and is prepared to implement measures to mitigate potential impacts on business development[126]. - The company faces risks related to the potential imitation of its main products, particularly Licorice tablets, which could impact its exclusive production status[119]. Talent and Human Resources - The company has established a comprehensive talent training system to support its strategic development, ensuring a stable and effective human resource base[37]. - The number of R&D personnel increased to 122, representing 9.19% of the total workforce, up from 7.40% in the previous period[110]. - The total compensation for R&D personnel was 22,040,538.32 RMB, with an average salary of 180,660.15 RMB, a decrease from 198,780.07 RMB in the prior period[110]. - The company emphasizes the importance of retaining core technical personnel, as their expertise is crucial for ongoing innovation and development[122]. Future Outlook - Future outlook indicates a projected revenue growth of 15% for the next fiscal year, driven by new product launches and market expansion strategies[193]. - The company plans to enhance its digital marketing efforts, aiming for a 40% increase in online sales channels[192]. - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market presence[192]. - The company is committed to upgrading production capacity and enhancing digital transformation through new project implementations[181].